Argos Therapeutics, Inc. (NASDAQ:ARGS) Stock Rating Upgraded by Zacks Investment Research
Argos Therapeutics, Inc. (NASDAQ:ARGS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
Other equities analysts have also recently issued reports about the stock. FBR & Co dropped their target price on shares of Argos Therapeutics from $2.00 to $1.20 and set a “mkt perform” rating for the company in a research report on Wednesday, April 19th. Stifel Nicolaus dropped their target price on shares of Argos Therapeutics to $1.20 and set a “hold” rating for the company in a research report on Friday, March 17th. Four research analysts have rated the stock with a hold rating, Argos Therapeutics currently has an average rating of “Hold” and a consensus price target of $3.23.
Shares of Argos Therapeutics (NASDAQ:ARGS) opened at 0.3252 on Tuesday. Argos Therapeutics has a 52 week low of $0.31 and a 52 week high of $7.08. The company’s market capitalization is $13.45 million. The firm’s 50-day moving average is $0.42 and its 200 day moving average is $2.09.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.